Amicus Therapeutics Inc (FOLD)
10.84
0.00 (0.00%)
USD |
NASDAQ |
Apr 23, 10:56
Amicus Therapeutics Cash from Investing (Quarterly): -23.96M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -23.96M |
| September 30, 2023 | 35.76M |
| June 30, 2023 | 50.00M |
| March 31, 2023 | 36.26M |
| December 31, 2022 | -66.70M |
| September 30, 2022 | 74.52M |
| June 30, 2022 | 26.29M |
| March 31, 2022 | 58.21M |
| December 31, 2021 | -68.09M |
| September 30, 2021 | 34.57M |
| June 30, 2021 | 25.71M |
| March 31, 2021 | 86.56M |
| December 31, 2020 | -22.78M |
| September 30, 2020 | -154.06M |
| June 30, 2020 | 70.01M |
| March 31, 2020 | 93.25M |
| December 31, 2019 | 26.96M |
| September 30, 2019 | 3.193M |
| June 30, 2019 | -15.07M |
| March 31, 2019 | 80.06M |
| December 31, 2018 | -63.80M |
| September 30, 2018 | 114.48M |
| June 30, 2018 | 10.73M |
| March 31, 2018 | -182.60M |
| December 31, 2017 | 51.53M |
| Date | Value |
|---|---|
| September 30, 2017 | -173.91M |
| June 30, 2017 | 43.55M |
| March 31, 2017 | -92.41M |
| December 31, 2016 | 35.34M |
| September 30, 2016 | -29.62M |
| June 30, 2016 | -9.797M |
| March 31, 2016 | -0.442M |
| December 31, 2015 | 85.41M |
| September 30, 2015 | -262.07M |
| June 30, 2015 | 9.655M |
| March 31, 2015 | 21.66M |
| December 31, 2014 | -79.73M |
| September 30, 2014 | -29.48M |
| June 30, 2014 | 7.935M |
| March 31, 2014 | -5.802M |
| December 31, 2013 | -7.966M |
| September 30, 2013 | 20.18M |
| June 30, 2013 | 7.10M |
| March 31, 2013 | 6.765M |
| December 31, 2012 | 16.61M |
| September 30, 2012 | -15.24M |
| June 30, 2012 | 15.88M |
| March 31, 2012 | -56.69M |
| December 31, 2011 | 15.69M |
| September 30, 2011 | 10.31M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-154.06M
Minimum
Sep 2020
93.25M
Maximum
Mar 2020
14.24M
Average
26.96M
Median
Dec 2019
Cash from Investing (Quarterly) Benchmarks
| TG Therapeutics Inc | -44.76M |
| Geron Corp | 47.57M |
| Vanda Pharmaceuticals Inc | -43.78M |
| Fate Therapeutics Inc | 45.35M |
| Editas Medicine Inc | 62.84M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 3.458M |
| Cash from Financing (Quarterly) | 8.21M |
| Free Cash Flow | -76.53M |
| Free Cash Flow Per Share (Quarterly) | 0.0057 |
| Free Cash Flow to Equity (Quarterly) | 7.94M |
| Free Cash Flow to Firm (Quarterly) | 13.65M |
| Free Cash Flow Yield | -2.39% |